Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has taken a step forward in its bid to protect a key gene therapy technology in Japan, as the country’s patent office moved a core application into the national examination stage.
The patent, covering variants of a gene known as SIRT6, which is linked to age-related diseases, was originally filed in May 2022.
It is jointly owned by three US academic institutions: the University of Rochester, Columbia University and Albert Einstein College of Medicine. Genflow holds the exclusive licence to develop and commercialise the invention.
SIRT6 plays a role in maintaining genomic stability and regulating how cells process energy, which are tied to the ageing process and the onset of related illnesses. The gene variants are central to Genflow’s lead therapeutic programme.
Eric Leire, Genflow’s chief executive, said: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property.
"Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy."
Brussels-based Genflow is listed in London and the US, and is the only publicly traded company in Europe focused exclusively on longevity treatments.